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Context: Low-grade inflammation is involved in the development of type 2 diabetes and
cardiovascular disease (CVD); however, prospective studies evaluating inflammatory markers as
predictors of changes in insulin secretion and insulin sensitivity are lacking.
Objective: We investigated the associations of glycoprotein acetyls (GlycA), interleukin-1 receptor
antagonist (IL-1RA), and high-sensitivity C-reactive protein (hs-CRP) with insulin secretion, insulin
sensitivity, incident type 2 diabetes, hypertension, CVD events, and totalmortality in the prospective
Metabolic Syndrome in Men (METSIM) study.
Design: A prospective study.
Participants: The cross-sectionalMETSIM study included 8749 nondiabetic Finnishmen aged 45 to 73
years, who had been randomly selected from the population register of Kuopio, Finland. A total of
5401 men participated in the 6.8-year follow-up study.
Main OutcomeMeasures: Changes in insulin secretion, insulin sensitivity, and cardiometabolic traits
during the follow-up period and the incidence of type 2 diabetes, hypertension, CVD events, and
total mortality.
Results:Duringthefollow-upperiod,GlycAwasassociatedwith impaired insulin secretion,hyperglycemia,
incident type 2 diabetes (hazard ratio, 1.37; 95% confidence interval, 1.29 to 1.46) and CVD (hazard ratio,
1.21; 95% confidence interval, 1.12 to 1.32). IL-1RA and hs-CRP were associated with adverse changes in
insulin sensitivity and obesity-related traits and with total mortality (hazard ratio, 1.13; 95% confidence
interval, 1.07 to 1.20; and hazard ratio, 1.08; 95% confidence interval, 1.04 to 1.11, respectively).
Conclusions: Inflammatory markers differentially predicted changes in insulin secretion and insulin
sensitivity. GlycA predicted impaired insulin secretion, and IL-1RA and hs-CRP predicted changes in
insulin sensitivity. Combining the three markers improved the prediction of disease outcomes,
suggesting that they capture different aspects of low-grade inflammation. (J Clin Endocrinol Metab
102: 3600–3609, 2017)
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Abbreviations: Apo, apolipoprotein; AUC, area under the curve; BMI, body mass index;
BP, blood pressure; CVD, cardiovascular disease; FPG, fasting plasma glucose; GlycA,
glycoprotein acetyls; 2hPG, 2-hour plasmaglucose; HbA1c, glycated hemoglobin; hs-CRP,
high-sensitivity C-reactive protein; HDL, high-density lipoprotein; IL-1, interleukin-1; IL-
1RA, interleukin-1 receptor antagonist; InsAUC0–30/GluAUC0–30, early-phase insulin
secretion index; ISI, insulin sensitivity index; LDL, low-density lipoprotein; METSIM,
Metabolic Syndrome inMen; OGTT, oral glucose tolerance test; PC, principal component;
PCA, principal component analysis; TAG, triacylglycerols.
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The incidence and prevalence of type 2 diabetes anddiabetes-related complications have been consistently
increasing worldwide; therefore, identifying those in-
dividuals at high risk of diabetes is of great importance.
Low-grade systemic inflammation is often associated
with insulin resistance and impaired insulin secretion, the
two key mechanisms underlying the pathophysiology of
type 2 diabetes (1, 2). Elevated levels of acute-phase
proteins, such as high-sensitivity C-reactive protein (hs-
CRP) and tumor necrosis factor-a are often already
present in those with prediabetes (3, 4) and are predictive
of future type 2 diabetes (5–7) and cardiovascular disease
(CVD) events (8, 9). Also, members of the interleukin-1
(IL-1) cytokine family, including IL-1 receptor antagonist
(IL-1RA), have been found to play a role in the patho-
genesis of type 2 diabetes by triggering obesity-induced
inflammation and exacerbating insulin resistance (10).
Additionally, IL-1RA levels have been shown to increase
gradually with worsening glycemia. In contrast, hs-CRP
increased only within the prediabetic range of glucose
levels (11). Recently, serum glycoprotein acetylation
levels, originating from the N-acetyl methyl groups of
N-acetylglucosamine residues, have been found as a
unique biomarker of systemic inflammation, because it
captures both circulating levels and complex glycosyla-
tion patterns of the most abundant acute-phase proteins
(12). The biomarker glycoprotein acetylation correlates
strongly with other markers of inflammation (13, 14).
In apparently healthy individuals, glycoprotein acetyls
(GlycA) can be chronically elevated for periods of up
to one decade, suggesting a prolonged low-grade in-
flammatory state (15). Elevated concentrations of GlycA
have been found in patients with type 2 diabetes (16, 17).
In large, prospective cohort studies, increased levels of
GlycA have been associated with type 2 diabetes (12, 18),
coronary heart disease (19, 20), and all-cause mortality,
independently of traditional risk factors (21, 22). Addi-
tionally, elevated levels ofGlycAhave been associatedwith
the deterioration of hyperglycemia in a 6.5-year follow-up
study of nondiabetic subjects (23) and with insulin re-
sistance in a cross-sectional study of 7098 young Finns
(24). However, no large population-based prospective
studies have evaluated GlycA as a predictor of changes in
insulin secretion, insulin sensitivity, or insulin resistance-
related traits. The aim of our 6.8-year follow-up studywas
to investigate the associations of three acute-phase pro-
teins, GlycA, hs-CRP, and IL-1RA, with the changes in
insulin sensitivity and insulin secretion in a large cohort of
men without known type 2 diabetes. Additionally, we
investigated the associations of these markers with insulin
resistance–related traits, incident type 2 diabetes, drug-
treated hypertension, CVD events, and total mortality.
Materials and Methods
Subjects
The Metabolic Syndrome in Men (METSIM) study in-
cluded 10,197 Finnish middle-aged men randomly selected
from the population register of Kuopio, Eastern Finland
(population, 105,000). The baseline study was performed
from 2005 to 2010 at the Clinical Research Unit, University of
Eastern Finland, Kuopio, Finland. The main study has been
previously described in detail (25). The present study included
8749 men without type 2 diabetes at baseline [mean age,
57.2 6 7.1 years; body mass index (BMI), 26.8 6 3.8 kg/m2].
Their baseline clinical and metabolic characteristics are pre-
sented in Table 1 as the means6 standard deviations. Glucose
tolerance was evaluated using a 2-hour oral glucose tolerance
test (OGTT) with 75 g of glucose after a 12-hour overnight
fast, and glucose tolerance status was classified according to
the American Diabetes Association criteria (26). Of the 10,197
men, 3034 (34.7%) had normal glucose tolerance, 4344
(49.7%) isolated impaired fasting glucose, 312 (3.6%) had
isolated impaired glucose tolerance, and 1059 (12.1%) had
both impaired fasting glucose and impaired glucose tolerance.
Men with type 1 diabetes (n = 25), previously diagnosed type 2
diabetes (n = 763), type 2 diabetes diagnosed at baseline (n = 649),
or missing OGTT data (n = 11) were excluded from the analyses.
The ethics committees of the University of Eastern Finland and
Kuopio University Hospital approved the present study, which
was conducted in accordance with the Declaration of Helsinki.
All study participants provided written informed consent. Two
datasets of the METSIM study were used in the prospective
analyses.
Data for prospective analysis of glycemic traits
A prospective follow-up study was started in 2010. To
date, 5401 men without diabetes at baseline or during the
follow-up period have been re-examined. The study protocol
and measurements were identical to those of the baseline
study.
Data for prospective analysis of incident type 2
diabetes, incident hypertension, CVD events, and
total mortality
Of the 8749 nondiabetic men at baseline, 693 developed
incident type 2 diabetes between the baseline and follow-up
studies. The diagnosis of new-onset type 2 diabetes was based
on the following: (1) fasting plasma glucose (FPG)$7.0 mmol/L),
2-hour plasma glucose (2hPG) level in anOGTTof$11.1mmol/L
or glycated hemoglobin (HbA1c) of $6.5% (diagnosing 327
new cases of diabetes) among nondiabetic men who partic-
ipated in the follow-up study; (2) antidiabetic medication
started between the baseline study and follow-up study
(revealing 261 new cases of diabetes; information obtained
from the National Drug Reimbursement registry for all 8749
nondiabetic men); or (3) type 2 diabetes diagnosed by a
physician according to the medical records and/or an FPG
of$7.0mmol/L, 2hPG of$11.1mmol/L, orHbA1c of$6.5%
in outpatient or primary care laboratory measurements (di-
agnosing 37 new cases of type 2 diabetes). The follow-up time
was calculated as the time in months between the date of the
METSIM baseline visit and the date of theMETSIM follow-up
visit or between the date of the METSIM baseline visit and the
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start date of antidiabetic medication or the date of the di-
agnosis of diabetes.
Of the 8749 nondiabetic men, 439 experienced a CVD event
during the follow-up study. An incident CVD event was defined
as nonfatal myocardial infarction, coronary heart disease,
death, or fatal and nonfatal cerebral infarction that had oc-
curred between the baseline and follow-up studies. CVD events
were defined according to the internationally accepted criteria
(27, 28), identified from hospital discharge registry, and verified
from the hospital medical records. Participants with a CVD
event before the baseline visit were excluded from the statistical
analyses. Of the 8749 nondiabetic men, 225 men started new
antihypertensive treatment after the baseline visit, and 392 men
died during the follow-up period. These data were obtained
from the National Drug Reimbursement registry and the
Finnish mortality registry, respectively. Nondiabetic men re-
ceiving antihypertensive treatment (n = 1537) at the baseline
study were excluded from the statistical analyses evaluating the
associations of acute-phase proteins (GlycA, IL-1RA, and hs-
CRP) with the development of drug-treated hypertension.
The average follow-up period (6.8 6 1.6 years) was calcu-
lated according to the different follow-up lengths for the dif-
ferent outcomes (e.g., OGTT-derived measures and incident
type 2 diabetes) according to the point at which the data
were obtained.
Clinical and laboratory measurements
The cross-sectional and follow-up studies of the MET-
SIM cohort used identical protocols and similar clinical
and laboratory measurements. All clinical and laboratory
measurements were performed twice, at the baseline ex-
amination and at the follow-up visit. Height was measured
to the nearest 0.5 cm and weight using a calibrated digital
scale (Seca 877; Seca, Hamburg, Germany) to the nearest
0.1 kg. The BMI was calculated as the weight in kilograms
divided by the height in square centimeters. The waist cir-
cumference was measured to the nearest 0.5 cm, with the
average of two measurements taken after inspiration and
expiration at the midpoint between the lowest rib and the
iliac crest. The body composition was determined using
bioelectrical impedance (Bioimpedance AnalyzerModel BIA
101; Akern SrL, Florence, Italy) with the subjects in the
supine position after a 12-hour overnight fast. The systolic
and diastolic blood pressures (BPs) were calculated as the
average of three measurements performed with the subject in
the sitting position after a 10-minute rest using a mercury
sphygmomanometer. Physical activity refers to leisure time
physical activity (physically active, regular exercise for $30
minutes one or more times weekly vs physically inactive,
occasional exercise, or no exercise). Smoking status was
defined as current smoking (yes vs no).
The plasma glucose was measured using an enzymatic
hexokinase photometric assay (Konelab Systems Reagents;
Thermo Fisher Scientific, Vantaa, Finland). Insulin was de-
termined by immunoassay (ADVIA Centaur Insulin IRI no.
02230141; SiemensMedical Solutions Diagnostics, Tarrytown,
NY). HbA1c was analyzed using high-performance liquid
chromatography on a Tosoh G7 glycohemoglobin analyzer
(Tosoh Bioscience, Inc., San Francisco, CA), which was cali-
brated according to the Diabetes Control and Complications
Trial standard. Total triacylglycerols (TAG), plasma free fatty
acids, high-density lipoprotein (HDL) cholesterol, and low-
density lipoprotein (LDL) cholesterol were measured using
enzymatic colorimetric tests (Konelab Systems Reagents;
Table 1. Clinical and Metabolic Characteristics of 8749 Men Without Type 2 Diabetes in the Baseline
METSIM Study
Baseline Study Variable Men, n Mean 6 SD IQR
Age, y 8749 57.18 6 7.07 51.00–63.00
BMI, kg/m2 8746 26.82 6 3.81 24.31–28.86
Waist circumference, cm 8745 97.43 6 10.60 90.00–103.50
Fat mass, % 8727 23.41 6 6.31 18.90–27.20
Systolic BP, mm Hg 8749 137.16 6 16.25 126.00–146.67
Diastolic BP, mm Hg 8749 87.21 6 9.26 80.67–92.67
LDL cholesterol, mmol/L 8746 3.37 6 0.88 2.76–3.92
HDL cholesterol, mmol/L 8747 1.46 6 0.39 1.17–1.67
TAG, mmol/L 8749 1.40 6 0.96 0.88–1.66
ApoA1, g/L 8747 1.41 6 0.24 1.25–1.55
ApoB, g/L 8747 1.04 6 0.27 0.85–1.19
Adiponectin, mg/mL 8747 7.94 6 4.37 5.30–9.50
ALT, U/L 8749 31.31 6 20.19 20.00–37.00
FPG, mmol/L 8749 5.71 6 0.48 5.40–6.00
2hPG, mmol/L 8749 6.05 6 1.69 4.90–7.00
Glucose AUC, mmol/L 3 min 8719 886.92 6 136.65 792.00–973.50
HbA1c, % 8727 5.67 6 0.33 5.50–5.90
InsAUC0–30/GluAUC0–30 8703 31.10 6 21.51 17.22–38.43
Matsuda ISI 8697 6.91 6 4.15 3.79–9.02
Disposition indexa 8697 163.51 6 71.90 113.37–197.96
GlycA, mmol/L 8716 1.36 6 0.23 1.21–1.47
hs-CRP, mg/L 8748 2.02 6 4.04 0.52–2.28
IL-1RA, mg/L 8748 0.21 6 0.17 0.13–0.25
Abbreviations: ALT, alanine aminotransferase; IQR, interquartile range; SD, standard deviation.
aDisposition index was calculated as Matsuda ISI 3 InsAUC0–30/GluAUC0–30.
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ThermoFisher Scientific, Vantaa, Finland). Serum concentrations
of hs-CRP were assayed using kinetic immunoturbidimetry (near
infrared particle immunoassay; IMMAGE Immunochemistry
System; Beckman Coulter, Fullerton, CA) and plasma IL1-RA
using a photometric immunoassay [enzyme-linked immunosor-
bent assay (ELISA)] method (Quantikine DRA00 Human
IL-1RA; R&D Systems, Inc., Minneapolis, MN). Plasma
adiponectin was measured using ELISA (human adiponectin
ELISA kit; Linco Research, St. Charles, MI), and alanine
aminotransferase by enzymatic photometric test (Konelab
Systems Reagents; Thermo Fisher Scientific). Apolipoproteins
A1 and B (ApoA1 and ApoB) were quantified using immu-
noturbidimetry (Konelab Systems Reagents; Thermo Fisher
Scientific). Concentrations of glycoprotein acetyls (including
mainly alpha-1-acid glycoprotein) were quantified from serum
samples using a high-throughput proton nuclear magnetic
resonance metabolomics platform, as previously described
(29). Information on the GlycA level was available for 8716 of
the 8749 nondiabetic men at the baseline study.
Calculations
The trapezoidal method was used to calculate the glucose
area under the curve (glucose AUC) using the OGTT samples
collected at 0, 30, and 120 minutes. The Matsuda insulin
sensitivity index (Matsuda ISI) (30) and early-phase insulin
secretion index (InsAUC0–30/GluAUC0–30) were calculated as
previously described (25). The disposition index (a marker of
insulin secretion) was calculated as the Matsuda ISI 3
InsAUC0–30/GluAUC0–30.
Statistical analysis
Statistical analyses were conducted using SPSS, version 19
(IBM Corp., Armonk, NY). All variables (except for age and
LDL cholesterol) were logarithmically transformed for statis-
tical analyses owing to their skewed distributions. The Spear-
man correlation was applied to explore the relationships
between GlycA, IL-1RA, and hs-CRP and the clinical and
metabolic traits in nondiabetic participants from the METSIM
baseline study. The Fisher r-to-z transformation was used to
compare the correlation coefficients. Linear regression analysis
was used to evaluate GlycA, IL-1RA, and hs-CRP as predictors
of changes in metabolic and clinical traits in a follow-up study.
The results are presented as unstandardized coefficients in
original units (B6 standard error) and standardized coefficient
(b). Linear regression models were initially adjusted for the
baseline level of the corresponding dependent trait, and an
additional adjustment was done for age, follow-up time (in
months), and BMI (except for the BMI, waist circumference,
and fat mass). Models that included the systolic and diastolic BP
were also adjusted for the use of antihypertensive medication at
baseline, and the model that included LDL cholesterol was
adjusted for statin medication use at baseline. Cox regression
analysis was used to evaluate the ability of GlycA, IL-1RA, and
hs-CRP to predict for incident type 2 diabetes, drug-treated
hypertension, CVD events, and total mortality. Hazard ratios
were calculated using standardized predictors, and hazard
ratios with their 95% confidence intervals are presented. The
Cox regression models were adjusted for age, BMI, smoking,
physical activity, and LDL cholesterol levels at baseline.
Table 2. Spearman Correlations of Acute-Phase Proteins With Baseline Clinical and Metabolic Traits in Men
Without Type 2 Diabetes in the METSIM Baseline Study
Baseline Study Variable
GlycA, mmol/L IL-1RA, mg/L hs-CRP, mg/L
Men, n r P Value Men, n r P Value Men, n r P Value
Age, y 8716 0.022 0.040a 8748 20.027 0.013a 8748 0.056 ,0.0001b
BMI, kg/m2 8713 0.308 ,0.0001b 8745 0.372c ,0.0001b 8745 0.332 ,0.0001b
Waist, cm 8712 0.334 ,0.0001b 8744 0.387 ,0.0001b 8744 0.365 ,0.0001b
Fat mass, % 8694 0.243 ,0.0001b 8726 0.279 ,0.0001b 8726 0.300 ,0.0001b
Systolic BP, mm Hg 8716 0.177c ,0.0001b 8748 0.049 ,0.0001b 8748 0.114 ,0.0001b
Diastolic BP, mm Hg 8716 0.197c ,0.0001b 8748 0.117 ,0.0001b 8748 0.136 ,0.0001b
LDL cholesterol, mmol/L 8716 0.169c ,0.0001b 8745 20.019 0.078 8745 0.108 ,0.0001b
HDL cholesterol, mmol/L 8716 20.344c ,0.0001b 8746 20.268 ,0.0001b 8746 20.178 ,0.0001b
TAG, mmol/L 8716 0.601c ,0.0001b 8748 0.240 ,0.0001b 8748 0.171 ,0.0001b
ApoA1, g/L 8716 20.063 ,0.0001b 8746 20.133c ,0.0001b 8746 20.095 ,0.0001b
ApoB, g/L 8716 0.416c ,0.0001b 8746 0.120 ,0.0001b 8746 0.185 ,0.0001b
Adiponectin, mg/mL 8714 20.169 ,0.0001b 8746 20.145 ,0.0001b 8746 20.101 ,0.0001b
ALT, U/L 8716 0.163 ,0.0001b 8748 0.249c ,0.0001b 8748 0.123 ,0.0001b
FPG, mmol/L 8716 0.132 ,0.0001b 8748 0.168c ,0.0001b 8748 0.060 ,0.0001b
2hPG, mmol/L 8716 0.212 ,0.0001b 8748 0.210 ,0.0001b 8748 0.138 ,0.0001b
Glucose AUC, mmol/L 3 min 8686 0.230 ,0.0001b 8718 0.229 ,0.0001b 8718 0.137 ,0.0001b
InsAUC0–30/GluAUC0–30 8670 0.302
c ,0.0001b 8702 0.243c ,0.0001b 8702 0.156c ,0.0001b
Matsuda ISI 8664 20.409c ,0.0001b 8696 20.353 ,0.0001b 8696 20.224 ,0.0001b
Disposition indexd 8664 20.177 ,0.0001b 8696 20.185 ,0.0001b 8696 20.119 ,0.0001b
Abbreviations: ALT, alanine aminotransferase; r, Spearman correlation coefficient.
aP , 0.05 was considered to indicate nominal statistical significance.
bBonferroni-adjusted P , 0.00088 was considered to indicate statistical significance (0.05/19 traits 3 3 acute-phase proteins).
cCorrelation coefficient was significantly (P , 0.05) different from correlation coefficients of other two acute-phase proteins with the same traits using
Fisher r-to-z transformation.
dDisposition index was calculated as Matsuda ISI 3 InsAUC0–30/GluAUC0–30.
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Principal component analysis (PCA) based on the correla-
tion matrix with varimax rotation was used to reduce a set of
three intercorrelated acute-phase proteins (GlycA, IL-1RA,
and hs-CRP) to a smaller set of underlying principal com-
ponents (PCs). The analysis yielded a single PC with an
eigenvalue $1, explaining 52% of the total variance, with
variable loadings of 0.760, 0.733, and 0.673 for hs-CRP,
GlycA, and IL-1RA, respectively. The PC score obtained
from the PCA was used in the Cox regression analysis as a
predictor of disease outcomes. Bonferroni correction for
multiple testing was performed to determine the statistical
significance of the results (threshold for P value given for
each analysis); P , 0.05 was considered to indicate nominal
statistical significance.
Results
Baseline characteristics of study participants
Our present report included the data from8749 Finnish
men (mean age, 57.26 7.1 years; BMI, 26.86 3.8 kg/m2)
without type 2 diabetes. The baseline GlycA level was
measured in 8716 men (99.6%), and the IL-1RA and hs-
CRP levels were measured in 8748 men (99.9%). The
baseline cardiometabolic characteristics of the study par-
ticipants relevant to the present study are summarized in
Table 1.
Correlations of acute-phase proteins with metabolic
and clinical traits in the METSIM baseline study
GlycA correlated significantly (Bonferroni-adjusted
P , 0.0009 for 19 traits 3 3 acute-phase proteins) and
positively with the baseline levels of IL-1RA (r = 0.246)
andhs-CRP (r =0.347). The correlationbetween the IL1-RA
and hs-CRP levels was r = 0.276. All three acute-phase
proteins correlated significantly and positivelywithmeasures
of obesity (BMI, waist circumference, and fat mass), TAG,
ApoB, glucose levels (FPG, 2hPG, and glucoseAUC), alanine
aminotransferase, and InsAUC0–30/GluAUC0–30, and nega-
tively with the Matsuda ISI, disposition index, HDL cho-
lesterol, and adiponectin level (Table 2). However, GlycA
correlated more strongly than did the other two acute-phase
proteins with TAG (r = 0.601), ApoB (r = 0.416), Matsuda
ISI (r = 20.409), InsAUC0–30/GluAUC0–30 (r = 0.302),
systolic and diastolic BP, and LDL and HDL cholesterol.
IL-1RA correlated more strongly with BMI (r = 0.372),
alanine aminotransferase (r = 0.249), and FPG (r = 0.168)
than did the other two acute-phase proteins and hs-CRP
showed the weakest correlation.
Association of acute-phase proteins with changes in
metabolic and clinical traits in the METSIM
follow-up study
We prospectively evaluated the associations of the
three acute-phase proteins (GlycA, IL-1RA, and hs-CRP)
with changes in selected cardiometabolic traits during
the follow-up period in men without type 2 diabetes
at baseline or diagnosed during the follow-up period
(Table 3). The GlycA level at baseline was significantly
(Bonferroni-adjusted P , 0.00093, 0.05/18 traits 3 3
predictors) associated with increases in FPG, 2hPG, and
glucose AUC and decreases in BMI and insulin secretion
(disposition index) during the follow-up period in both
models without and with covariates. IL-1RA was sig-
nificantly associated with increases in waist circumfer-
ence, fat mass, diastolic BP, InsAUC0–30/GluAUC0–30,
Table 3. Association of Acute-Phase Proteins Measured at Baseline With Changes in Metabolic and Clinical
Traits During 6.8-Year Follow-Up Study of Men Without Previously Diagnosed Type 2 Diabetes
Trait at Follow-Up Study
GlycA, mmol/L
Men, n Ba SEa bb P Valuec P Valued
BMI, kg/m2 5383 20.336 0.098 20.019 0.0006e 0.0004e
Waist, cm 5383 20.172 0.338 20.003 0.640 0.458
Fat mass, % 5336 0.833 0.327 0.032 0.002f ,0.0001e
Systolic BP, mm Hg 5381 2.236 0.917 0.038 0.003f 0.845
Diastolic BP, mm Hg 5381 1.635 0.527 0.041 0.001f 0.055
LDL cholesterol, mmol/L 5383 20.156 0.047 20.041 0.0005e 0.058
HDL cholesterol, mmol/L 5383 0.008 0.016 20.006 0.460 0.869
TAG, mmol/L 5383 0.205 0.046 0.028 0.031f 0.073
ApoA1, g/L 5089 20.036 0.012 20.032 0.003f 0.060
ApoB, g/L 5089 0.024 0.014 0.007 0.552 0.229
Adiponectin, mg/mL 1299 20.663 0.531 20.046 0.025f 0.119
ALT, U/L 5383 1.630 0.892 0.020 0.053 0.313
FPG, mmol/L 5383 0.247 0.031 0.092 ,0.0001e ,0.0001e
2hPG, mmol/L 5383 0.863 0.110 0.089 ,0.0001e ,0.0001e
Glucose AUC, mmol/L 3 min 5341 70.392 8.058 0.100 ,0.0001e ,0.0001e
InsAUC0–30/GluAUC0–30 5310 20.667 1.117 20.006 0.668 0.023
f
Matsuda ISI 5303 20.634 0.218 20.034 0.0005e 0.043f
Disposition indexg 5303 223.44 3.719 20.084 ,0.0001e ,0.0001e
(continued across on facing page )
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and TAG and a decrease in the Matsuda ISI in both
models. hs-CRP was significantly associated with in-
creases in the fat mass, TAG, InsAUC0–30/GluAUC0–30,
2hPG, and glucose AUC and a decrease inMatsuda ISI in
both models.
Association of acute-phase proteins with incident
type 2 diabetes, new-onset drug-treated
hypertension, CVD events, and total mortality
GlycA significantly (P, 0.003, 0.05/4 outcomes3 4
predictors) predicted for incident type 2 diabetes and
CVD events in both unadjusted and adjusted (for age,
BMI, smoking status, physical activity, and LDL cho-
lesterol) Cox regression models (Table 4). IL-1RA
predicted for total mortality and hs-CRP predicted for
both total mortality and CVD events in the unadjusted
model; however, these associations were attenuated to
nominally statistically significant (P , 0.05) after ad-
justment for covariates. In addition, a single PC ob-
tained from the PCA of all three acute-phase proteins
was the strongest predictor of incident type 2 diabetes,
CVD events, and total mortality in both unadjusted and
adjusted models.
Discussion
We evaluated the associations of three acute-phase
proteins, GlycA, IL-1RA, and hs-CRP, at baseline with
insulin secretion, insulin sensitivity, and insulin resistance-
related traits, and with disease outcomes, including in-
cident type 2 diabetes, drug-treated hypertension, CVD
events, and total mortality in initially nondiabetic men
from the 6.8-year follow-up portion of the METSIM
cohort. These three acute-phase proteins differed in their
associations with glucose metabolism-related parame-
ters and the risk of type 2 diabetes, CVD, and total
mortality. The important findings from our study are as
follows: (1) the GlycA levels were associated with a de-
crease in insulin secretion and increases in glucose levels
(FPG, 2hPG, and glucose AUC) compared with IL-1RA
and hs-CRP levels, which were associated with a decrease
in insulin sensitivity, and increases in waist circumference
and/or fat mass, and TAG; (2) GlycA was the best pre-
dictor of incident type 2 diabetes and CVD events among
the three acute-phase proteins; and (3) combining the
three markers improved the prediction of type 2 diabetes,
CVD events, and total mortality. These results suggest
Table 3. Continued
IL-1RA, mg/L hs-CRP, mg/L
Men, n ba SEa bb P Valuec P Valued Men, n Ba SEa bb P Valuec P Valued
5400 0.213 0.143 0.015 0.008f 0.017f 5400 0.006 0.005 20.004 0.480 0.989
5400 1.768 0.487 0.035 ,0.0001e ,0.0001e 5400 0.039 0.017 0.021 0.003f 0.0003e
5352 1.848 0.468 0.035 0.0006e ,0.0001e 5352 0.055 0.016 0.075 ,0.0001e ,0.0001e
5398 3.343 1.298 0.026 0.036f 0.001f 5398 0.104 0.046 0.058 ,0.0001e 0.011f
5398 5.138 0.745 0.098 ,0.0001e 0.0002e 5398 0.029 0.027 0.050 0.0001e 0.451
5399 20.004 0.066 0.010 0.385 0.046f 5399 0.000 0.002 20.024 0.039f 0.740
5399 0.014 0.022 20.013 0.109 0.727 5399 0.001 0.001 20.011 0.169 0.994
5400 0.241 0.054 0.091 ,0.0001e ,0.0001e 5400 0.005 0.002 0.071 ,0.0001e ,0.0001e
5105 20.047 0.017 20.043 0.0001e 0.006f 5105 0.002 0.001 0.013 0.239 0.006f
5105 0.042 0.020 0.033 0.005f 0.012f 5105 0.002 0.001 0.028 0.014f 0.003f
1303 22.033 0.736 20.073 0.0003e 0.014f 1302 0.026 0.037 20.011 0.587 0.905
5400 3.530 1.294 0.035 0.001f 0.046f 5400 0.027 0.045 0.008 0.469 0.989
5400 0.102 0.045 0.023 0.049f 0.026f 5400 20.001 0.002 0.052 ,0.0001e 0.434
5400 0.850 0.156 0.072 ,0.0001e 0.002f 5400 0.012 0.006 0.079 ,0.0001e ,0.0001e
5358 51.27 11.53 0.049 ,0.0001e 0.294 5358 0.606 0.408 0.072 ,0.0001e 0.0003e
5327 3.870 1.555 0.025 ,0.0001e 0.003f 5327 0.112 0.055 0.020 ,0.0001e 0.022f
5320 20.637 0.303 20.061 ,0.0001e 0.0003e 5320 20.011 0.010 20.066 ,0.0001e ,0.0001e
5320 217.54 5.352 20.050 ,0.0001e 0.145 5320 20.205 0.189 20.060 ,0.0001e 0.004f
Abbreviations: ALT, alanine aminotransferase; b, standardized regression coefficient; SE, standard error.
aEffect sizes (b, SE) are in original units.
bb coefficients are standardized; P values and b coefficients were calculated using logarithmically transformed variables (except for age and LDL
cholesterol).
cP values adjusted for the baseline level of the corresponding dependent trait.
dP values additionally adjusted for age, follow-up time, and BMI (except for BMI, waist, and fat mass); systolic and diastolic BP were additionally adjusted
for antihypertensive medication at baseline, and LDL cholesterol for statin medication at baseline.
eBonferroni-adjusted P , 0.00093 was considered to indicate statistical significance (0.05/18 traits 3 3 predictors).
fP , 0.05 was considered to indicate nominal statistical significance.
gDisposition index was calculated as Matsuda ISI 3 InsAUC0–30/GluAUC0–30.
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that all three acute-phase proteins capture early changes
in cardiometabolic traits before the diagnosis of diabetes.
Impaired insulin secretion and insulin resistance in
multiple tissues are the two key mechanisms in the
pathophysiology of type 2 diabetes. Several population-
based studies have confirmed that low-grade systemic
inflammation and increased levels of markers of in-
flammation such as hs-CRP, IL-6, tumor necrosis factor-
a, and IL-1RA are already present in those with pre-
diabetes (11, 31). Prospective studies have also shown
that chronic low-grade inflammation precedes frank di-
abetes (7, 32). However, no large prospective studies
have simultaneously evaluated several acute-phase pro-
teins (e.g., GlycA, IL-1RA, and hs-CRP) as predictors for
changes in insulin secretion, insulin resistance, and in-
sulin resistance-related traits. In a recent cross-sectional
analysis that included 1225 participants from the Insulin
Resistance Atherosclerosis Study (IRAS), GlycA, sialic
acid (GlycB), and C-reactive protein levels were associ-
ated with insulin sensitivity but not with insulin secretion,
measured by a frequently sampled intravenous glucose
tolerance test and adjusted for insulin sensitivity (33).
Our cross-sectional METSIM study included a seven-
fold larger sample size and showed that GlycA, IL-1RA,
and hs-CRP correlated significantly, not only with the
Matsuda ISI, but also with the disposition index (insulin
secretion adjusted for insulin sensitivity). Additionally,
our prospective analysis demonstrated that the baseline
levels of GlycA predicted for a decrease in the disposition
index, but not in the Matsuda ISI, after adjustment for
confounding factors. Our findings emphasize the need for
large prospective population-based studies to investigate
the role of inflammatory markers in metabolic changes
over time.
Increased levels of circulating markers of inflamma-
tion, including acute-phase proteins, have been pre-
viously associated with the risk of type 2 diabetes and
CVD in large cross-sectional (11, 34) and follow-up (5, 6,
9, 35) studies. GlycA, a glycan biomarker of low-grade
inflammation, has been found to predict for type 2 di-
abetes in a 7.3-year follow-up analysis of the Prevention
of Renal and Vascular End-stage Disease (PREVEND)
study (12) and in a large population of initially healthy
women (18). Moreover, GlycA levels have been asso-
ciated with incident CVD events and CVD mortality
(19, 21). However, none of the previous follow-up studies
has simultaneously evaluated the associations of multiple
acute-phase proteins with type 2 diabetes, several adverse
cardiovascular outcomes, and total mortality.
We have demonstrated that GlycA is the strongest
predictor of an increase in glycemia (FPG, 2hPG, and
glucose AUC), incident type 2 diabetes, and CVD events
after the adjustment for confounding factors among the
three acute-phase proteins. Additionally, GlycA corre-
lated strongly with several cardiovascular and diabetes
risk factors at baseline (including TAG,Matsuda ISI, and
LDL and HDL cholesterol), and significantly predicted
for a decrease in insulin secretion during the follow-up
period in men without previously diagnosed diabetes.
The measurement of GlycA using proton nuclear mag-
netic resonance incorporates the signal from several
acute-phase reactants and immunologic proteins and,
therefore, represents an integrated plasma biomarker.
Furthermore, GlycA reflects an altered enzymatic gly-
cosylation pattern, which plays an important role in the
pathogenesis of low-grade inflammation–related diseases
such as atherosclerosis, metabolic syndrome, and di-
abetes (36–39). Altogether, GlycA could reflect the risk
associated with a summation of multiple pathways of
low-grade systemic inflammation and, thus, predict for
early changes in glucose metabolism and cardiometabolic
traits and, consequently, in the risk of type 2 diabetes and
CVD, as demonstrated in our study. However, additional
studies are needed to explore in detail the pathways
underlying the associations we observed in our study.
IL-1RA and hs-CRP were not associated with an in-
creased risk of incident type 2 diabetes after adjustment
for confounding factors in our 6.8-year follow-up study
but nominally significantly predicted total mortality. Also,
hs-CRP nominally significantly predicted CVD events.
Accordingly, IL-1RA and hs-CRP were predominantly
associated with adverse changes in adiposity (waist cir-
cumference and fat mass) and insulin sensitivity but not in
insulin secretion (disposition index) during the follow-up
Table 4. Association ofAcute-Phase ProteinsMeasured at BaselineWith Incident Type 2Diabetes, New-Onset
Drug-Treated Hypertension, CVD Events, and Total Mortality in a 6.8-Year Follow-Up METSIM Study
Variable
GlycA IL-1RA
NTOTAL/EVENT HR (95% CI) P Value
a P Valueb NTOTAL/EVENT HR (95% CI)
Type 2 diabetes 8716/690 1.37 (1.29–1.46) ,0.0001c ,0.0001c 8748/692 1.18 (1.15–1.22)
Hypertension drug treatment 7147/224 1.17 (1.04–1.32) 0.009d 0.974 7170/225 1.07 (0.97–1.19)
CVD events 8320/437 1.21 (1.12–1.32) ,0.0001c 0.003c 8351/439 1.09 (1.02–1.17)
Total mortality 8716/390 1.16 (1.06–1.27) 0.001c 0.077 8748/392 1.13 (1.07–1.20)
(continued across on facing page )
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period. Elevated levels of IL-1RA and hs-CRP are gen-
erally considered to indicate a proinflammatory state. The
major source of circulating IL-1RA is adipose tissue
(10, 40), and increased levels of IL-1RA are often found in
obese individuals. IL-1 family members are known to
play a role in the pathology of type 2 diabetes by triggering
obesity-induced inflammation (10, 40). hs-CRP has also
been related to adiposity and insulin resistance (3, 33),
which might explain the association of IL-1RA and hs-
CRP with adverse changes in adiposity and insulin sen-
sitivity in our prospective study.
The PCA that included all three acute-phase proteins
resulted in a single PC that was a better predictor of
incident type 2 diabetes, CVD events, and total mortality
than any of the markers used individually. This also
suggests that the three markers capture different aspects
of low-grade inflammation and that combining them
improves the risk prediction.
The strengths of our study were that it used data from a
large well-characterized cohort of men with a long follow-
up period. Furthermore, insulin sensitivity and secretion
were measured by indexes validated against reference
standard measurements. One limitation of our study was
that, because we included only middle-aged and elderly
Finnish men, we could not ensure the applicability of our
results to women or other populations. Therefore, at-
tempts should be made to replicate our results in women,
other ethnic groups, and other age groups.
Conclusions
In the present study, we have demonstrated that the three
acute-phase proteins examined differentially predicted
for changes inmetabolic parameters and the risk of type 2
diabetes and cardiovascular outcomes. GlycA predicted
for impaired insulin secretion, incident type 2 diabetes,
and CVD events and adverse changes in glycemia during
the follow-up period. IL-1RA and hs-CRP were associ-
ated with an increase in insulin resistance and obesity
markers during the follow-up period, suggesting that
these threemarkers capture different aspects of low-grade
inflammation. The combined effect of all three acute-
phase proteins improved the prediction of incident type 2
diabetes, CVD events, and total mortality compared with
the markers used individually.
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